Global Obesity Drug Market Analysis
Single User PDF Format: US$ 1,000.00
Multi-User License: US$ 1,500.00
Hard Copy: US$ 1,100.00
CD-ROM: US$ 1,100.00
The obesity epidemic has been disseminating among developed countries as well as low-income and middle-income countries. The main factor responsible for the propagation of this disease in the middle and low income countries is the result of new dietary habits and sedentary ways of life, fuelling chronic diseases, and premature mortality. As per WHO, the obese population is forecasted to reach around 700 Million by the end of 2015 from around 500 Million in 2008, which signifies immense opportunities for the players entering this market. Consequently, the obesity drug market is expected to be worth US$ 2.5 Billion by the end of 2014.
According to our report “Global Obesity Drug Market Analysis”, one of the main factors that has been surging the revenue is the heavy R&D spending on the discovery of new drugs. During the last few years, various obesity drugs have been banned by the FDA and various other regulatory bodies on grounds of safety reasons. The drugs have been identified causing serious side effects, such as liver damage, early stage heart disease, and many more. As a result, the drug manufacturers are heavily investing on the research and development of new drugs, which poses minimum or no side effects on the patients.
Further, North America and Europe are expected to be largest obesity drug market as they constitute some of the fattest nations such as, the US, Mexico, Germany etc. As obesity and related morbidities have huge medical costs associated with it, the governments in these regions have been taking rigorous steps to control this pandemic, which further fuels the growth of the market in these regions.
Our report also provides information of the key competitors in the market along with their business information and areas of expertise. The report shows a highly concentrated structure of the market, with the top players dominating the market. It provides segment level analysis of the industry along with the emerging trends that may shape up with the betterment of economic conditions.
The research will help consultants, industry analysts, and vendors to get in-depth knowledge of the current, past, and future performance of the industry. The report provides an extensive research on the recent trends of the global obesity drug market along with an impartial analysis considering the impact of financial crisis on its performance.
Multi-User License: US$ 1,500.00
Hard Copy: US$ 1,100.00
CD-ROM: US$ 1,100.00
The obesity epidemic has been disseminating among developed countries as well as low-income and middle-income countries. The main factor responsible for the propagation of this disease in the middle and low income countries is the result of new dietary habits and sedentary ways of life, fuelling chronic diseases, and premature mortality. As per WHO, the obese population is forecasted to reach around 700 Million by the end of 2015 from around 500 Million in 2008, which signifies immense opportunities for the players entering this market. Consequently, the obesity drug market is expected to be worth US$ 2.5 Billion by the end of 2014.
According to our report “Global Obesity Drug Market Analysis”, one of the main factors that has been surging the revenue is the heavy R&D spending on the discovery of new drugs. During the last few years, various obesity drugs have been banned by the FDA and various other regulatory bodies on grounds of safety reasons. The drugs have been identified causing serious side effects, such as liver damage, early stage heart disease, and many more. As a result, the drug manufacturers are heavily investing on the research and development of new drugs, which poses minimum or no side effects on the patients.
Further, North America and Europe are expected to be largest obesity drug market as they constitute some of the fattest nations such as, the US, Mexico, Germany etc. As obesity and related morbidities have huge medical costs associated with it, the governments in these regions have been taking rigorous steps to control this pandemic, which further fuels the growth of the market in these regions.
Our report also provides information of the key competitors in the market along with their business information and areas of expertise. The report shows a highly concentrated structure of the market, with the top players dominating the market. It provides segment level analysis of the industry along with the emerging trends that may shape up with the betterment of economic conditions.
The research will help consultants, industry analysts, and vendors to get in-depth knowledge of the current, past, and future performance of the industry. The report provides an extensive research on the recent trends of the global obesity drug market along with an impartial analysis considering the impact of financial crisis on its performance.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. UNDERSTANDING OBESITY PANDEMIC
4. MARKET TRENDS
4.1 Increasing Prevalence of Obesity
4.2 Heavy R&D Spending
4.3 Strategic Alliances
4.4 Emerging New Treatments
4.4.1 Drug Combos
4.4.2 Cannabinoids
4.4.3 Information and Communication Technologies
5. GLOBAL OBESITY DRUG MARKET: INDUSTRY PERFORMANCE
5.1 Market Overview
5.2 Major Drugs
5.2.1 Orlistat/Xenical
5.2.2 Meridia
5.2.3 Acomplia
5.2.4 Alli
5.3 Future Obesity Drug Pipeline
5.3.1 Liraglutide
5.3.2 Armodafinil
5.3.3 Sulfamethoxazole/trimethoprim
5.3.4 IHBG-10
5.4 Top Selling Weight-Loss Supplements
6. REGIONAL LEVEL DEVELOPMENTS
6.1 North America
6.1.1 US
6.1.2 Mexico
6.1.3 Canada
6.2 Latin America
6.2.1 Brazil
6.3 Europe
6.3.1 UK
6.3.2 France
6.3.3 Germany
6.4 Asia-Pacific
6.4.1 Australia
6.4.2 New Zealand
6.4.3 India
6.4.4 China
6.5 Middle East and Africa
6.5.1 UAE
6.5.2 Qatar
6.5.3 Saudi Arabia
6.5.4 South Africa
7. COMPETITIVE LANDSCAPE
7.1 F Hoffmann-La Roche Ltd
7.2 Abbott Laboratories
7.3 AstraZeneca Plc
7.4 Sanofi-Aventis SA
7.5 Takeda Pharmaceutical Company Limited
2. RESEARCH METHODOLOGY
3. UNDERSTANDING OBESITY PANDEMIC
4. MARKET TRENDS
4.1 Increasing Prevalence of Obesity
4.2 Heavy R&D Spending
4.3 Strategic Alliances
4.4 Emerging New Treatments
4.4.1 Drug Combos
4.4.2 Cannabinoids
4.4.3 Information and Communication Technologies
5. GLOBAL OBESITY DRUG MARKET: INDUSTRY PERFORMANCE
5.1 Market Overview
5.2 Major Drugs
5.2.1 Orlistat/Xenical
5.2.2 Meridia
5.2.3 Acomplia
5.2.4 Alli
5.3 Future Obesity Drug Pipeline
5.3.1 Liraglutide
5.3.2 Armodafinil
5.3.3 Sulfamethoxazole/trimethoprim
5.3.4 IHBG-10
5.4 Top Selling Weight-Loss Supplements
6. REGIONAL LEVEL DEVELOPMENTS
6.1 North America
6.1.1 US
6.1.2 Mexico
6.1.3 Canada
6.2 Latin America
6.2.1 Brazil
6.3 Europe
6.3.1 UK
6.3.2 France
6.3.3 Germany
6.4 Asia-Pacific
6.4.1 Australia
6.4.2 New Zealand
6.4.3 India
6.4.4 China
6.5 Middle East and Africa
6.5.1 UAE
6.5.2 Qatar
6.5.3 Saudi Arabia
6.5.4 South Africa
7. COMPETITIVE LANDSCAPE
7.1 F Hoffmann-La Roche Ltd
7.2 Abbott Laboratories
7.3 AstraZeneca Plc
7.4 Sanofi-Aventis SA
7.5 Takeda Pharmaceutical Company Limited
LIST OF FIGURES:
Figure 4-1: Global - Obese Population Aged above 15 Years (Million), 2008 & 2015
Figure 5-1: Global - Obesity Drug Market (Billion US$), 2010-2014
Figure 5-2: Global - Orlistat/Xenical Sales (Million US$), 2008-2010
Figure 5-3: Global - Meridia Sales (Million US$), 2008-2010
Figure 5-4: Global - Acomplia Sales (Million US$), 2007 & 2008
Figure 5-5: Global - Alli Sales (Million GBP), 2008-2010
Figure 6-1: US - Obesity Prevalence (%), 2009 & 2015
Figure 6-2: Mexico - Overweight and Obesity Prevalence (%), 2000 & 2006
Figure 6-3: Canada - Obese Population (Million), 2007-2009
Figure 6-4: Brazil - Obesity Prevalence (%), 2002-03 & 2008-09
Figure 6-5: UK - Obesity Prevalence (%), 2009, 2015 & 2025
Figure 6-6: UK - Obesity Prevalence in Children (%), 2007-08 to 2009-10
Figure 6-7: France - Obesity Prevalence (%), 2003, 2006 & 2009
Figure 6-8: Germany - Overweight and Obesity Prevalence (%), 2008
Figure 6-9: Australia - Obesity Prevalence (%), 2006-07 & 2007-08
Figure 6-10: Australia - Obesity Prevalence in Children Aged 7-15 Years (%), 1985, 1995 & 2007
Figure 6-11: New Zealand - Obesity Prevalence (%), 1997, 2003 & 2007
Figure 6-12: India - Overweight Prevalence (%), 2005 & 2015
Figure 6-13: India - Obesity Drug Market (Billion INR), 2009-2011
Figure 6-14: Qatar - Obesity Prevalence (%), 2003, 2005 & 2010
LIST OF TABLE:
Table 3-1: Risk of Co-morbidities based on BMI Levels
Table 6-1: US - Obesity Prevalence by Age Group (%), 2009
Table 6-2: Mexico - Overweight and Obesity Prevalence in Children by Age Group (%), 2006
Table 6-3: Brazil - Obesity Prevalence by Age Group (%), 2008-09
Table 6-4: Australia - Cost of Obesity (Billion US$), 2008-09
Table 6-5: South Africa - Overweight Prevalence in Top Cities (%)
Table 7-1: F Hoffmann-La Roche Ltd - SWOT Analysis
Table 7-2: Abbott Laboratories - SWOT Analysis
Table 7-3: AstraZeneca Plc - SWOT Analysis
Table 7-4: Sanofi-Aventis SA - SWOT Analysis
Table 7-5: Takeda Pharmaceutical Company Limited - SWOT Analysis
Figure 4-1: Global - Obese Population Aged above 15 Years (Million), 2008 & 2015
Figure 5-1: Global - Obesity Drug Market (Billion US$), 2010-2014
Figure 5-2: Global - Orlistat/Xenical Sales (Million US$), 2008-2010
Figure 5-3: Global - Meridia Sales (Million US$), 2008-2010
Figure 5-4: Global - Acomplia Sales (Million US$), 2007 & 2008
Figure 5-5: Global - Alli Sales (Million GBP), 2008-2010
Figure 6-1: US - Obesity Prevalence (%), 2009 & 2015
Figure 6-2: Mexico - Overweight and Obesity Prevalence (%), 2000 & 2006
Figure 6-3: Canada - Obese Population (Million), 2007-2009
Figure 6-4: Brazil - Obesity Prevalence (%), 2002-03 & 2008-09
Figure 6-5: UK - Obesity Prevalence (%), 2009, 2015 & 2025
Figure 6-6: UK - Obesity Prevalence in Children (%), 2007-08 to 2009-10
Figure 6-7: France - Obesity Prevalence (%), 2003, 2006 & 2009
Figure 6-8: Germany - Overweight and Obesity Prevalence (%), 2008
Figure 6-9: Australia - Obesity Prevalence (%), 2006-07 & 2007-08
Figure 6-10: Australia - Obesity Prevalence in Children Aged 7-15 Years (%), 1985, 1995 & 2007
Figure 6-11: New Zealand - Obesity Prevalence (%), 1997, 2003 & 2007
Figure 6-12: India - Overweight Prevalence (%), 2005 & 2015
Figure 6-13: India - Obesity Drug Market (Billion INR), 2009-2011
Figure 6-14: Qatar - Obesity Prevalence (%), 2003, 2005 & 2010
LIST OF TABLE:
Table 3-1: Risk of Co-morbidities based on BMI Levels
Table 6-1: US - Obesity Prevalence by Age Group (%), 2009
Table 6-2: Mexico - Overweight and Obesity Prevalence in Children by Age Group (%), 2006
Table 6-3: Brazil - Obesity Prevalence by Age Group (%), 2008-09
Table 6-4: Australia - Cost of Obesity (Billion US$), 2008-09
Table 6-5: South Africa - Overweight Prevalence in Top Cities (%)
Table 7-1: F Hoffmann-La Roche Ltd - SWOT Analysis
Table 7-2: Abbott Laboratories - SWOT Analysis
Table 7-3: AstraZeneca Plc - SWOT Analysis
Table 7-4: Sanofi-Aventis SA - SWOT Analysis
Table 7-5: Takeda Pharmaceutical Company Limited - SWOT Analysis
